loading page

Stem cell-based therapy for rheumatoid arthritis
  • Maryam Moghaddam1,
  • Mohammad Javad Mousavi,
  • Somayeh Ghotloo
Maryam Moghaddam1
Shahid Sadoughi University of Medical Sciences Yazd Reproductive Sciences Institute
Author Profile
Mohammad Javad Mousavi
Boushehr University of Medical Sciences
Author Profile
Somayeh Ghotloo
Kashan University of Medical Sciences Faculty of Health

Corresponding Author:[email protected]

Author Profile

Abstract

Autoimmune diseases, including systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), and systemic sclerosis (SSc) are the most prevalent rheumatic autoimmune disorders affecting autologous connective tissues caused by the breakdown of the self-tolerance mechanisms of the immune system. During the last two decades, stem cell therapy has been increasingly considered as a therapeutic option in various diseases, including parkinson’s disease, alzheimer, stroke, spinal cord injury, multiple sclerosis, inflammatory bowel disease, liver disease, diabete, heart disease, bone disease, renal disease, respiratory diseases, and hematological abnormalities such as anemia. This is due to the unique properties of stem cells that divide and differentiate to the specialized cells in the damaged tissue. Moreover, they impose immunomodulatory properties affecting the diseases caused by immunological abnormalities such as rheumatic autoimmune disorders. In the present review, efficacy of stem cell therapy with two main types of stem cells, including mesenchymal stem cells, and hematopoietic stem cells in animal models or human patients of one common rheumatic autoimmune diseases, including, RA, will be reviewed. Moreover, other related issues, including safety, changes in immunological parameters, suitable choice of stem cell origin, conditioning regimen, limitations, and complications of stem cell treatment will be discussed.
09 Apr 2023Submitted to Immunity, Inflammation and Disease
18 Apr 2023Submission Checks Completed
18 Apr 2023Assigned to Editor
20 Apr 2023Review(s) Completed, Editorial Evaluation Pending
24 Apr 2023Reviewer(s) Assigned
22 May 2023Editorial Decision: Revise Major
28 Aug 20231st Revision Received
30 Aug 2023Assigned to Editor
30 Aug 2023Review(s) Completed, Editorial Evaluation Pending
30 Aug 2023Submission Checks Completed
30 Aug 2023Reviewer(s) Assigned
07 Sep 2023Editorial Decision: Revise Minor
19 Sep 20232nd Revision Received
20 Sep 2023Submission Checks Completed
20 Sep 2023Assigned to Editor
20 Sep 2023Review(s) Completed, Editorial Evaluation Pending
20 Sep 2023Reviewer(s) Assigned
29 Sep 2023Editorial Decision: Revise Minor
30 Oct 20233rd Revision Received
02 Nov 2023Assigned to Editor
02 Nov 2023Submission Checks Completed
02 Nov 2023Review(s) Completed, Editorial Evaluation Pending
02 Nov 2023Reviewer(s) Assigned
03 Nov 2023Editorial Decision: Accept